iBio (IBIO) Competitors $1.03 +0.07 (+7.29%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IBIO vs. ANVS, CNTX, KLTO, CLSD, TELO, DTIL, ICCC, VNRX, KLRS, and GANXShould you be buying iBio stock or one of its competitors? The main competitors of iBio include Annovis Bio (ANVS), Context Therapeutics (CNTX), Klotho Neurosciences (KLTO), Clearside Biomedical (CLSD), Telomir Pharmaceuticals (TELO), Precision BioSciences (DTIL), ImmuCell (ICCC), VolitionRx (VNRX), Allovir (KLRS), and Gain Therapeutics (GANX). These companies are all part of the "pharmaceutical products" industry. iBio vs. Its Competitors Annovis Bio Context Therapeutics Klotho Neurosciences Clearside Biomedical Telomir Pharmaceuticals Precision BioSciences ImmuCell VolitionRx Allovir Gain Therapeutics iBio (NYSE:IBIO) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, community ranking, risk, analyst recommendations, valuation, earnings and institutional ownership. Do institutionals & insiders have more ownership in IBIO or ANVS? 7.9% of iBio shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 0.6% of iBio shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media favor IBIO or ANVS? In the previous week, Annovis Bio had 14 more articles in the media than iBio. MarketBeat recorded 14 mentions for Annovis Bio and 0 mentions for iBio. Annovis Bio's average media sentiment score of 0.66 beat iBio's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the news media. Company Overall Sentiment iBio Neutral Annovis Bio Positive Which has more volatility & risk, IBIO or ANVS? iBio has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Do analysts prefer IBIO or ANVS? iBio presently has a consensus target price of $4.30, suggesting a potential upside of 317.48%. Annovis Bio has a consensus target price of $30.25, suggesting a potential upside of 925.42%. Given Annovis Bio's higher probable upside, analysts plainly believe Annovis Bio is more favorable than iBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iBio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer IBIO or ANVS? Annovis Bio received 28 more outperform votes than iBio when rated by MarketBeat users. Likewise, 91.43% of users gave Annovis Bio an outperform vote while only 44.44% of users gave iBio an outperform vote. CompanyUnderperformOutperformiBioOutperform Votes444.44% Underperform Votes555.56% Annovis BioOutperform Votes3291.43% Underperform Votes38.57% Is IBIO or ANVS more profitable? Annovis Bio's return on equity of 0.00% beat iBio's return on equity.Company Net Margins Return on Equity Return on Assets iBioN/A -73.15% -45.51% Annovis Bio N/A N/A -311.00% Which has preferable valuation and earnings, IBIO or ANVS? iBio has higher revenue and earnings than Annovis Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiBio$375K45.37-$24.91MN/AN/AAnnovis BioN/AN/A-$56.20M-$2.16-1.37 SummaryAnnovis Bio beats iBio on 11 of the 14 factors compared between the two stocks. Get iBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBIO vs. The Competition Export to ExcelMetriciBioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$17.02M$6.92B$5.61B$19.87BDividend YieldN/A2.55%5.28%3.83%P/E RatioN/A8.6727.1435.60Price / Sales45.37262.53411.8343.81Price / CashN/A65.8538.2517.51Price / Book0.736.597.064.85Net Income-$24.91M$143.75M$3.23B$1.02B7 Day Performance11.17%3.72%2.67%1.94%1 Month Performance30.15%11.01%8.82%3.02%1 Year Performance-59.92%3.87%31.44%9.87% iBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBIOiBio1.148 of 5 stars$1.03+7.3%$4.30+317.5%-61.0%$17.02M$375K0.00100Gap UpANVSAnnovis Bio2.1302 of 5 stars$3.07-4.5%$30.25+886.3%-58.5%$59.76MN/A-0.693News CoverageAnalyst ForecastAnalyst RevisionGap UpCNTXContext Therapeutics3.0923 of 5 stars$0.70+5.8%$6.00+753.6%-69.7%$59.57MN/A-0.777News CoveragePositive NewsGap UpHigh Trading VolumeKLTOKlotho NeurosciencesN/A$1.82+787.8%N/AN/A$59.14MN/A-5.06N/AGap UpHigh Trading VolumeCLSDClearside Biomedical2.7076 of 5 stars$0.76-3.2%$4.80+530.7%-35.4%$59.14M$3.76M-1.6930Positive NewsShort Interest ↓High Trading VolumeTELOTelomir Pharmaceuticals2.0293 of 5 stars$1.98-7.9%$15.00+657.6%-64.2%$58.93MN/A-3.411High Trading VolumeDTILPrecision BioSciences4.2091 of 5 stars$5.30-3.5%$47.00+786.8%-57.8%$58.77M$51.14M88.35200News CoveragePositive NewsICCCImmuCell0.5754 of 5 stars$6.42-1.7%N/A+45.6%$58.02M$27.30M-12.8470Short Interest ↓VNRXVolitionRx2.0419 of 5 stars$0.56+0.5%$3.75+573.6%-23.6%$57.35M$1.31M-1.5580News CoverageAnalyst UpgradeGap UpKLRSAllovirN/A$3.06-7.3%N/AN/A$57.23MN/A0.00110Analyst DowngradeGap UpHigh Trading VolumeGANXGain Therapeutics2.3383 of 5 stars$1.91-0.5%$8.20+329.3%-26.3%$57.20M$50K-1.7420 Related Companies and Tools Related Companies ANVS Alternatives CNTX Alternatives KLTO Alternatives CLSD Alternatives TELO Alternatives DTIL Alternatives ICCC Alternatives VNRX Alternatives KLRS Alternatives GANX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IBIO) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
